Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (SKB264-Fru-GA)
2026年7月7日 更新者:Ting Deng、Tianjin Medical University Cancer Institute and Hospital
Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With Fruquintinib as Second-Line Therapy for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
This is a phase 2 multicenter study that will evaluate the safety and efficacy of sacituzumab tirumotecan (Sac-TMT) plus fruquintinib for the treatment of participants with locally advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma who have failed 1 prior line of therapy.
調査の概要
研究の種類
介入
入学 (推定)
45
段階
- フェーズ2
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前:Ting Deng, MD
- 電話番号:15802243063
- メール:xymcdengting@126.com
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
- Histologically and/or cytologically confirmed metastatic or locally advanced adenocarcinoma of the gastric or gastroesophageal junction, unresectable;
- Subjects who have failed first-line standard systemic therapy, or experienced disease progression or recurrence within 6 months after completion of adjuvant systemic therapy (HER2-positive subjects must have received prior anti-HER2 therapy);
- Have at least one measurable lesion per RECIST v1.1, subjects with only cutaneous or bone lesions are not eligible for enrollment;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 within 7 days prior to study drug administration;
- Estimated life expectancy > 12 weeks.
Adequate organ and bone marrow function (no transfusions, recombinant human thrombopoietin or colony-stimulating factor administered within 2 weeks prior to dosing), defined as follows:
- Hematology: Absolute neutrophil count (NEUT#) ≥ 1.5×10⁹/L; platelets (PLT) ≥ 80×10⁹/L; hemoglobin ≥ 90 g/L;
- Hepatic function: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN); for subjects with baseline liver metastases, ALT and AST ≤ 5 × ULN; albumin ≥ 30 g/L; total bilirubin (TBIL) ≤ 1.5 × ULN;
- Renal function: Creatinine clearance ≥ 50 mL/min (calculated using the standard Cockcroft-Gault formula);
- Coagulation function: International normalized ratio (INR), activated partial thromboplastin time (APTT) and prothrombin time (PT) ≤ 1.5 × ULN.
- All acute toxicities from prior treatments have recovered to Grade 1 or lower (alopecia and vitiligo are excluded). Note: Subjects with any grade of prior endocrine adverse events may be enrolled if they only require maintenance hormone replacement therapy and are stable and asymptomatic at screening.
- Females of childbearing potential and males with partners of childbearing potential must agree to use effective medical contraception from the time of informed consent signature through 6 months after the last dose of study drug;
- The subject voluntarily participates in this study, signs the informed consent form, and is able to comply with protocol-specified study visits and related procedures.
Exclusion Criteria:
- Participants unable to receive oral administration due to dysphagia, intractable vomiting, or known drug malabsorption;
- Participants with active gastric/duodenal ulcer, ulcerative colitis, intestinal obstruction, or other gastrointestinal disorders/conditions judged by the Investigator to carry a risk of gastrointestinal hemorrhage or perforation; or with a history of intestinal perforation or fistula within the preceding 6 months; or with unresolved intestinal perforation/fistula following prior surgical repair;
- Participants with known meningeal metastasis, brainstem metastasis, spinal cord metastasis and/or spinal cord compression, or active/untreated central nervous system (CNS) metastases. Participants with previously locally treated brain metastases may be enrolled if clinically stable for at least 4 weeks prior to dosing and not requiring corticosteroids or anticonvulsants for a minimum of 14 days before the first dose;
- Participants diagnosed with another malignant tumor within 3 years prior to dosing, except malignancies cured by local therapy such as basal cell carcinoma of the skin, cutaneous squamous cell carcinoma, carcinoma in situ of the cervix, etc.;
Participants with clinically significant cardiovascular disease, defined as:
- Severe or uncontrolled cardiac disease or symptomatic cardiac conditions requiring treatment within 6 months prior to the first study dose, including congestive heart failure classified as New York Heart Association (NYHA) Class III or IV, medically refractory unstable angina, severe arrhythmias requiring pharmacotherapy (excluding atrial fibrillation or paroxysmal supraventricular tachycardia), and myocardial infarction;
- Prior history of myocarditis or cardiomyopathy;
- Baseline corrected QT (QTc) interval > 480 ms;
- Participants with a history of arterial thromboembolism or deep vein thrombosis within the preceding 6 months;
- Participants with documented or historical significant bleeding within 2 months prior to dosing, including melena, hematemesis, hemoptysis, ≥++ fecal occult blood. Subjects with 1+ fecal occult blood and underlying primary gastrointestinal lesions must complete gastroscopy prior to enrollment to rule out active bleeding or ulcers;
- Participants with a history of stroke and/or transient ischemic attack (TIA) within 12 months prior to dosing;
- Participants with severe and/or uncontrolled systemic diseases, such as unregulated metabolic disorders, active inflammatory bowel disease, or gastrointestinal perforation;
- Participants with active hepatitis B [hepatitis B surface antigen (HBsAg)-positive, with HBV-DNA ≥1000 IU/mL or above the lower limit of quantification (LLOQ), whichever is higher] or hepatitis C (hepatitis C antibody-positive with HCV-RNA above the LLOQ). Note: HBsAg-positive subjects must receive anti-HBV antiviral therapy throughout study treatment;
- Participants with known poorly controlled human immunodeficiency virus (HIV) infection; subjects with active syphilis infection;
- Participants with known active pulmonary tuberculosis;
- Participants who have undergone major surgery (as defined by the Investigator) within 30 days prior to the first study dose, or are still in the postoperative recovery phase from prior surgery;
- Participants with a history of severe hypersensitivity reactions to the study drug (including its excipients);
- Participants with a history of non-infectious interstitial lung disease (ILD) or non-infectious pneumonitis requiring steroid therapy; current ILD or non-infectious pneumonitis; or suspected ILD/non-infectious pneumonitis that cannot be ruled out via imaging at screening;
- Participants with a history of allogeneic tissue/organ transplantation;
Participants previously treated with any of the following regimens (including adjuvant or neoadjuvant settings):
- TROP2-targeted therapy;
- Any therapy containing topoisomerase I inhibitors, including antibody-drug conjugates (ADCs);
- Systemic therapy targeting the vascular endothelial growth factor receptor (VEGFR) signaling pathway;
- Participants who received live vaccines within 30 days prior to dosing, or plan to receive live vaccines during the study period;
- Participants requiring strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers within 2 weeks before the first dose and throughout the study;
- Participants who received chemotherapy, radiotherapy, immunotherapy, or biotherapy within 4 weeks before the first study dose;
- Participants who received small-molecule tyrosine kinase inhibitors (TKIs), anti-tumor hormonal therapy, systemic immune stimulants (including but not limited to interferon, IL-2), or proprietary Chinese medicines with approved anti-tumor indications within 2 weeks before the first study dose;
- Participants with active infection requiring systemic anti-infective therapy within 2 weeks prior to dosing;
- Participants with any disease requiring systemic corticosteroids (>10 mg prednisone equivalent daily) or other immunosuppressants within 14 days before the first study drug administration. Nasal, inhaled, topical, intra-articular corticosteroids, and corticosteroids administered for prophylaxis of infusion reactions are permitted;
- Participants with documented severe dry eye syndrome, severe meibomian gland disease and/or blepharitis, or corneal disorders with a history of impaired/delayed corneal wound healing;
- Pregnant or breastfeeding women, or women of childbearing potential with a positive pregnancy test prior to the first dose;
- Participants with urine protein ≥2+ and 24-hour urinary protein >1 g; or with uncontrolled hypertension despite antihypertensive medication (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg);
- Any other condition that, in the Investigator's judgment, renders the subject unsuitable for participation in this study.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Sac TMT + Fruquintinib
Following a 21 day run-in with sacituzumab tirumotecan at 4 mg/kg IV infusion on day 1 of a 2-week cycle plus fruquintinib at 3 mg QD PO on days 1-21 of a 4-week cycle, participants receive sacituzumab tirumotecan at 4 mg/kg IV infusion on day 1 of a 2-week cycle plus fruquintinib at 3 mg QD PO on days 1-21 of a 4-week cycle until discontinuation.
|
Sac TMT: 4mg/kg Q2W, IV Infusion Fruquinitinib: 3mg QD PO, d1-21, Q4W
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants who Experience Dose Limiting Toxicities (DLTs) During the Safety Lead-In Phase
時間枠:Up to ~21 days
|
DLTs are defined as any drug-related adverse event (AE) according to the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0, observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle.
The percentage of participants who experience at least one DLT will be presented.
|
Up to ~21 days
|
|
Objective Response Rate (ORR)
時間枠:Up to 2 years
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1).
The percentage of participants who experience CR or PR as assessed by investigators will be presented.
|
Up to 2 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression Free Survival (PFS)
時間枠:Up to 2 years
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by RECIST 1.1.
PD is defined as ≥20% increase in the sum of diameters of target lesions.
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm.
The appearance of one or more new lesions is also considered PD.
PFS as assessed by investigators will be presented.
|
Up to 2 years
|
|
Duration of Response (DOR)
時間枠:Up to 2 years
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death.
Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions.
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
The appearance of one or more new lesions is also considered PD.
DOR as assessed by investigators will be presented.
|
Up to 2 years
|
|
Disease Control Rate (DCR)
時間枠:up to 2 years
|
DCR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions), Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) or Stable Disease (SD: less than a 30% decrease and less than a 20% increase in the sum of diameters of target lesions, with no new lesions identified) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1).
|
up to 2 years
|
|
Overall Survival (OS)
時間枠:up to 3 years
|
OS is defined as the time from the date of enrollment to the date of death from any cause.
OS will be presented.
|
up to 3 years
|
|
Safety of combinatinal treatment
時間枠:up to 2 years
|
Percentage of participants who experience a treatment-related AE during the efficacy phase.
An AE is any untoward medical occurrence in a clinical study participant which is considered related to the use of the study intervention.
|
up to 2 years
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Exploration of Efficacy predictors
時間枠:up to 2 years
|
Tumor tissue and plasma specimens will be collected from patients at baseline, upon disease response and at disease progression for exploratory analyses of efficacy-related biomarkers.
|
up to 2 years
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2026年7月31日
一次修了 (推定)
2027年8月31日
研究の完了 (推定)
2028年12月31日
試験登録日
最初に提出
2026年6月30日
QC基準を満たした最初の提出物
2026年7月7日
最初の投稿 (実際)
2026年7月8日
学習記録の更新
投稿された最後の更新 (実際)
2026年7月9日
QC基準を満たした最後の更新が送信されました
2026年7月7日
最終確認日
2026年7月1日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。